Skip to main content

Table 2 Serum concentrations of thyroid hormones, TSH and TRAb in Graves’ patients during 24 years of continuous long-term MMI treatment

From: Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial

 

Baseline

Years of very long-term MMI treatment

1

5

10

15

20

24

Number

27

27

27

27

27

16

11

Serum fT4 (pmol/L)*

39.1 ± 9.2

16.9 ± 2.3

16.3 ± 2.3

16.2 ± 2.4

16.1 ± 2.5

16.3 ± 2.4

16.2 ± 2.2

Serum T3 (ng/dL)*

401 ± 126

135 ± 18

127 ± 18

129 ± 21

125 ± 18

123 ± 17

124 ± 17

Serum TSH (mU/L)

 Mean ± SD

All < 0.1

1.5 ± 1.6

2.5 ± 1.6

2.6 ± 1.6

2.5 ± 1.0

2.4 ± 1.2

2.7 ± 0.7

 Median (IQR)

All < 0.1

0.6 (0.2–2.4)

2.4 (1.0–3.1)

2.5 (1.5–3.3)

2.5 (1.9–3.1)

2.5 (1.8–2.9)

2.8 (2.6–3.1)

Serum TRAb (IU/mL)

 Mean ± SD

14.0 ± 7.0

1.2 ± 0.7

1.2 ± 0.6

1.1 ± 0.6

1.0 ± 0.6

1.0 ± 0.5

0.9 ± 0.4

 Median (IQR)

1.2 (0.6–1.4)

1.1 (0.5–1.4)

1.0 (0.4–1.3)

0.9 (0.4–1.2)

  1. *Values are mean ± standard deviation
  2. Normally distributed values. Serum concentrations of TSH and TRAb were in normal range after 6 years of treatment
  3. fT4 free thyroxine, T3 triiodothyronine, TSH thyrotropin, TRAb TSH receptor antibody, MMI methimazole